2-CdA in the treatment of hairy cell leukaemia.
BACKGROUND
Hairy cell leukaemia (HCL) is a rare lymphoproliferative disorder. Treatment options available are splenectomy, interferon, DCF and 2-CdA. 2-CdA is considered to have curative potential as proved by the other studies.


METHODS
We gave 2-CdA in a dose of 0.09/kg/day as a continuous infusion in sixteen patients of hairy cell leukaemia.


RESULTS
Three patients developed neutropenia post transfusion. At the end of three months all patients were in remission. Two patients relapsed at the median follow-up of 15 months.


CONCLUSIONS
2-CdA in HCL can achieve complete remission, prolonged survival and care as well.
Abhyankar
D
D
Department of Medical Oncology, Tata Memorial Hospital, Mumbai.
Bajpai
S
S
Saikia
T
T
Gopal
R
R
Nair
C N
CN
Advani
S H
SH
D015762:2-Chloroadenosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D003839:Deoxyadenosines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D015996:Survival Rate; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D003839:Deoxyadenosines; D015762:2-Chloroadenosine; C055994:2-chloro-3'-deoxyadenosine